A comparison of the efficacy of Symbicort (R) [budesonide/formoterol] single inhaler therapy (Symbicort Turbuhaler (R) 160/4.5 Mg 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26 weeks, randomised, open-label, parallel-group multicentre study.
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2017
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms STYLE
- Sponsors AstraZeneca
- 28 Jul 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 11 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2006 New trial record.